Skip to main navigation Skip to search Skip to main content

Correction: Structure-based design, optimization, and evaluation of potent stabilized peptide inhibitors disrupting MTDH and SND1 interaction (Journal of Medicinal Chemistry (2022) 65:18 (12188-12199) DOI: 10.1021/acs.jmedchem.2c00862)

  • Hailing Chen
  • , Meimiao Zhan
  • , Jianbo Liu
  • , Zhihong Liu
  • , Minhong Shen
  • , Fenfang Yang
  • , Yibin Kang
  • , Feng Yin
  • , Zigang Li

Research output: Contribution to journalComment/debatepeer-review

Abstract

Page 12198. Instead of The authors declare no competing financial interest , the following Note should be included: The authors declare the following competing financial interest(s): Y.K. is a founder and equity holder of Firebrand Therapeutics, Inc, which is developing inhibitors against MTDH/SND1. Received.

Original languageEnglish (US)
Pages (from-to)7668
Number of pages1
JournalJournal of Medicinal Chemistry
Volume66
Issue number11
DOIs
StatePublished - Jun 8 2023

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Correction: Structure-based design, optimization, and evaluation of potent stabilized peptide inhibitors disrupting MTDH and SND1 interaction (Journal of Medicinal Chemistry (2022) 65:18 (12188-12199) DOI: 10.1021/acs.jmedchem.2c00862)'. Together they form a unique fingerprint.

Cite this